Cases and Conversations™: Utilizing Real-World Evidence to Optimize Outcomes in Type 2 Diabetes – Reducing CV Events and Patient Hospitalizations With COVID-19 Considerations

Target Audience
This educational program is directed toward primary care physicians, diabetologists, endocrinologists, cardiologists, certified diabetes educators, nurse practitioners, and physician assistants; other health care providers who treat patients with T2DM will also be invited to participate.

Program Overview
Although impaired glucose metabolism has a central role in the pathology of cardiovascular (CV) complications in people with type 2 diabetes (T2D), several studies have demonstrated that CV risk cannot necessarily be reduced by achieving a normal serum glucose goal. Recent trials have provided valuable insights concerning the cardiovascular benefits of some antidiabetes medications, such as sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide 1 (GLP-1) agonists. In fact, the American Diabetes Association (ADA) now recommends that, in addition to metformin, patients with T2D and established (ASCVD) should receive a glucose-lowering drug shown to reduce major CV events.

This Community Practice Connection™ program provides an in-depth review of some of the key highlights from the Cases & Conversations™: Utilizing Real-World Evidence to Optimize Outcomes in Type 2 Diabetes – Reducing CV Events and Patient Hospitalizations with COVID-19 Considerations held in April 2021. This unique and engaging multimedia activity is ideal for the community-based clinician and focuses on the practical aspects managing patients with T2D and cardiovascular disease, putting recent clinical trial data into clinical context. The program is designed for those who did not attend the live meeting and to help reinforce learnings for those who did.

Learning Objectives
Upon completion of this activity, participants should be better able to:

Examine current treatment guidelines for patients with T2D for effective management of cardiovascular risk
Evaluate the real-world evidence for reducing cardiovascular events and hospitalizations to improve outcomes for patients with T2D
Apply emerging clinical data on issues in management of T2D in patients with COVID-19 toward the development of treatment plans